Asahi Kasei (China) Investment Co. Ltd.

To evaluate the bioequivalence of KT-611 tablets 25 mg produced by Asahi Kasei Pharma Corporation, Japan and Natuo tablets 25 mg produced by Nanjing Meirui Pharmaceutical Co., Ltd., China in healthy Chinese male subjects in the fasting and fed states.

To evaluate the bioequivalence of KT-611 tablets 25 mg produced by Asahi Kasei Pharma Corporation of Japan and "Standid" tablets 25 mg produced by Beijing Shuanglu Pharmaceutical Co., Ltd. of China in healthy Chinese male subjects under fasting and fed conditions.

A controlled study evaluating HE-69 versus cyclophosphamide (CTX) was conducted to observe its efficacy and safety and obtain data on the use of HE-69 in the treatment of patients with lupus nephritis, thereby supporting the expansion of HE-69 indications in China.